SK bioscience Co.,Ltd.

SK bioscience provides the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and globally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine.

Its portfolio also includes Skycellflu 4-ga pre-filled syringe, pneumococcal vaccine for adult and infant, Skyzoster, a shingles virus vaccine, and Sky Baricella for the prevention of chickenpox infection in children The development of oral rotavirus vaccine that has completed phase 2 clinical trial.

Its portfolio also includes cervical cancer vaccine, which has completed phase 2 clinical trial, rotavirus vaccine that is in phase 3 clinical trial in Africa, typhoid conjugate vaccine, Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials, and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea. is a subsidiary of SK Chemicals Co.,Ltd.